Newsroom

Dr. Martin Leon Accepts Executive Advisor Role with Corindus Vascular Robotics as External Consultant

2 years ago

Dr. Leon’s experience and knowledge will be crucial to the execution of the company’s roadmap

WALTHAM, Mass.–(BUSINESS WIRE)–

Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that Martin Leon, MD, one of the preeminent thought leaders in the field of interventional cardiology, has joined the company as an external consultant and executive advisor.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160419006581/en/

Dr. Leon is the Director of the Center for Interventional Vascular Therapy, Director of the Cardiac Catheterization Laboratories, and an Executive board member of the New York-Presbyterian Heart Valve Center. Dr. Leon is a practicing interventional cardiologist at New York-Presbyterian Hospital in New York City and is the founder and Chairman Emeritus of the Cardiovascular Research Foundation (CRF). Dr. Leon has been a principal driver in the emergence and success of many technologies, including drug-eluting stents and transcatheter aortic valve replacement (TAVR).

Martin Leon, MD

Dr. Leon has served as principal investigator for over 50 clinical trials that have helped shape the field of interventional cardiovascular medicine, has co-authored over 1,550 publications, has performed over 10,000 interventional procedures, and has had a major impact as a thought-leader and innovator in expanding the sub-specialty of interventional cardiovascular devices and drug therapies. He is Director and founder of Transcatheter Cardiovascular Therapeutics, the world’s premier interventional cardiovascular meeting, which recently celebrated its 26th anniversary.

“Throughout my years as a practicing interventional cardiologist, I have had an opportunity to play a role in the development of a number of critical technologies in the field, which is why I am excited about the opportunity to be a part of the growing field of robotics,” said Dr. Leon. “I look forward to working with Mark Toland and the rest of the Corindus team in continuing to drive the future of robotics in the cath lab and helping to establish it as another significant improvement in patient care.”

As an external consultant and executive advisor for Corindus, Dr. Leon will advise the Corindus executive team on technology development, clinical research strategy, and growth strategy including partnerships and alliances. He also will continue in his role as a practicing interventional cardiologist and a leader of CRF.

In making the announcement, Corindus President and CEO Mark Toland said, “We are extremely pleased and honored to formalize our relationship with Dr. Leon. Corindus values the tremendous experience and perspective he brings to his role as an advisor with our company and we look forward to his many contributions to our continued growth. We view the development of robust partnerships with thought leaders such as Dr. Leon as a key part of our future growth strategy.”

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company’s CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to radial coronary, and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus’ financial results is included from time to time in the “Forward Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Corindus’ periodic and current filings with the SEC, as well as those discussed under the “Risk Factors” and “Forward Looking Statements” section of Corindus’ Annual Report on Form 10-K filed with the SEC on March 11, 2016 and available on Corindus’ website at http://www.corindus.com/about-corindus/investor-relations. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.

MULTIMEDIA AVAILABLE:http://www.businesswire.com/news/home/20160419006581/en/

Contact:
Corindus Vascular Robotics
Media Contacts:
Brett Prince, 508-653-3335 ext. 231
VP Marketing
Brett.prince@corindus.com
or
Yuliya Kutuzava, 203-504-8230 ext. 131
corindus@knbcomm.com
or
Investor Contact:
Lynn Pieper Lewis, 415-309-5999
ir@corindus.com

Stock Information

Investor Toolkit

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address